BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (August 2014)
24 slides from BioSpecifics Technologies's investor presentation, Aug 27, 2014
Slide 1: Innovators in the development & commercialization of injectable collagenase
° \4 Innovators in the development & commercialization of ‘INJECTABLE COLLAGENASE —_—-~ . BioSpecifics August 2014
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”
Slide 3: Corporate Overview
Corporate Overview BioSpecifics is a profitable, commercial-stage biopharma company maximizing the potential of injectable collagenase for multiple indications XIAFLEX® (collagenase clostridium histolyticum or CCH) is now marketed for two indications in the U.S. by strategic partner, Auxilium Pharma
Slide 4: Vast Therapeutic Potential of CCH
Vast Therapeutic Potential of CCH CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications: Dupuytren’s contracture’ Froze
Slide 5: Approved Indications for XIAFLEX
Approved Indications for XIAFLEX Marketed ,, Dupuytren’s Multi-cord sBLA PDUFA date is October 20, 2014 Contracture ert we Potential decision in late 1Q15 on MAA filed by Sobi Disease Source: Auxilium Pharmaceuticals, Inc.
Slide 6: XIAFLEX for Dupuytren's Contracture
XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand Definition and One or more fingers caused to contract toward the palm Key Complications Limits range of motion of the fingers often resulting in physical disability and impaired quality of life First and Only Approved in th
Slide 7: Label Expansion Opportunity
Label Expansion Opportunity » SDI Health LLC estimates 35 to 40% of Dupuytren’s contracture surgeries in U.S. are performed to treat two or more cords Pre-treatment: concurrently a PDUFA date: October 20, 2014 ~ FDA to decide on sBLA, submitted by Auxilium, for XIAFLEX label expansion to allow multi
Slide 8: XIAFLEX for Peyronie's Disease
XIAFLEX for Peyronie’s Disease Excess of inelastic collagen causing penile curvature deformity Definition & Results in pain with erection, penile shortening, indentations, erectile Key Complications dysfunction and/or difficulty with sexual intercourse Potential loss of self-esteem and depression fo
Slide 9: Launch Progress
Launch Progress Focused, disciplined product rollout 5,000-6,500 patients receive invasive treatment for Peyronie’s disease each year (surgery or verapamil injections ) ~400 urologists performed about 90% of PD surgeries REMS certification of urologists 1,108 645 Total Physicians Certified Total Sit
Slide 10: Launch Progress Cont.
Launch Progress Cont. Reimbursement approval by payers (Auxilium Advantage) All eight Medicare beneficiaries confirmed coverage at policy level; 29 major commercial health plans have approved patients for treatment Listed as 'medically necessary’ in Clinical Policy Bulletin, when administered under
Slide 11: XIAFLEX Pipeline Programs
XIAFLEX Pipeline Programs frozen Top-line data in 1015 Shoulder ae ci Lipoma *) Human Complete enrollment in Phase 2 trial in 1Q15 Lipoma Cellulite Initiation of Phase 2b trial in 2Q15 *Uterine Fibroids *BioSpecifics-managed development program
Slide 12: CCH for Canine and Human Lipomas
CCH for Canine and Human Lipomas BioSpecifics-Managed Programs Encapsulated deposits of benign fatty tumors Definition and : Detected as bulges under the skin that occur in both humans and dogs Key Complications Can be serious health problem in dogs, restricting motion in older dogs Potential to be
Slide 13: Chien-804 Placebo-Controlled Phase 2 Trial in Canines
Chien-804 Placebo-Controlled Phase 2 Trial in Canines BioSpecifics reported data from placebo-controlled, randomized Phase 2 trial for CCH in canines with benign subcutaneous lipomas Study did not meet primary endpoint but demonstrated benefit in secondary measures: Responder analysis: » Visible sur
Slide 14: Dose Escalation Phase 2 Clinical Trial in Humans
Dose Escalation Phase 2 Clinical Trial in Humans BioSpecifics reported data from open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combinin
Slide 15: CCH for Uterine Fibroids
CCH for Uterine Fibroids Study Results Expected in 4Q14 Benign tumors with significant co- Definition & morbidlees Pain, decreased fertility, miscarriage, Key Complications heavy menstrual bleeding and frequent urination Potential to be Primary indication for hysterectomy in . U.S., accounting for b
Slide 16: CCH for Frozen Shoulder Syndrome
CCH for Frozen Shoulder Syndrome Top-line Data from Phase 2b Study Expected in 1Q15 Inflammation and thickening of ta shoulder capsule due to collagen Definition and Secretion Key Complications Limits the range of motion of the shoulder and painful Potential to be Common available treatment option i
Slide 17: Statistically Significant CCH Dose Response in Phase 2a Study
Statistically Significant CCH Dose Response in Phase 2a Study 60 + 1 Statistically significant improvements in H <0.05 Compari onward Flexion both the 0.58 mg(1mL) and 0.58 550 | to Exorcion: Cobar =F) shctaierAbsuciOn mg(2mL) cohorts over baseline scores 3 ©) External Rotation vs. the exercise-only
Slide 18: CCH for Cellulite
CCH for Cellulite Phase 2a Study Results Reported in 3Q14 Skin dimpling as a result of collagen fibrous septae held in an irregular pattern Definition under the skin, occurring mainly on the buttocks, lower limbs, and abdomen Significant Market Affects 85-98% of women (est.) and rarely in men Opport
Slide 19: CCH for Cellulite
CCH for Cellulite Initiation of Phase 2b Study Expected in 2Q15 Top-line Data from Phase 2a Study Demonstrated improvement in the appearance of cellulite in all dose groups based on physician and patient assessments; statistically significant in the mid and high dose groups 68% of mid and high dose
Slide 20: Auxilium Partnership for Development and Commercialization of CCH
Auxilium Partnership for Development and Commercialization of CCH >$45.1M Received Over $45M total received in licensing, sublicensing, milestone, COGS, and from Auxilium royalty payments as of June 30, 2014 Frrcre Payments Low double digit royalties as % of net sales by Auxilium Additional mark coG
Slide 21: Corporate Highlights
Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: » Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in U.S. until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 Peyronie’s Disease: Aux
Slide 22: Consistently Profitable Annually
Consistently Profitable Annually 2Q14 Financial Highlights For the quarter For the year ended ended 06/30/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments $ 16,633,708 $ 12,591,825 Income Statement Revenues $ 2,652,505, $ 14,467,240 Other income 7,352 26,202 Costs and
Slide 23: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones Steady Momentum in BioSpecifics-Managed Indications Upcoming Milestones *Human Lipomas Ocomplete enrollment in Phase 2 placebo-controlled opt-in trial in 1Q15 waar rae . (120 day opt-in period for Auxilium to license rights ends in 4Q14 ene Q Report pre-clinical study
Slide 24: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercializationof | Qs ECTABLE = (fe COLLAGEN Gail B ioSpecifics August 2014 TECHNOLOGIES CORP.
Biospecifics Technologies — Investor Presentation (August 2014) on 6ix